Advice
Following a resubmission
buprenorphine transdermal patches (Butrans®) are not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics.
Clinical effectiveness has not been demonstrated in the patient population under consideration in the resubmission.
The licence holder has indicated their intention to resubmit.
Download detailed advice91KB (PDF)
Medicine details
- Medicine name:
- buprenorphine transdermal patches (BuTrans)
- SMC ID:
- 234/06
- Indication:
- Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 07 May 2007